Carregant...
Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma
Opinion statement Treatment for relapsed/refractory (R/R) Hodgkin and non-Hodgkin lymphoma remains challenging. The introduction of rituximab to B cell non-Hodgkin lymphoma (B-NHL) treatment significantly improved patients’ response rate and survival; however, approximately one third of patients wit...
Guardat en:
| Publicat a: | Curr Treat Options Oncol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5578701/ https://ncbi.nlm.nih.gov/pubmed/27193488 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-016-0401-9 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|